Preserved bevacizumab (Avastin®) eye drops for application in multidose containers – an in-vitro characterisation
Abstract Purpose Monoclonal antibodies have made an immense contribution to the treatment of various human diseases. We aimed at investigating an affordable treatment option for veterinary patients with corneal neovascularization by adding the preservative benzalkonium chloride (BAC) to bevacizumab...
Saved in:
| Main Authors: | Ulrike Lessiak, Tania Brandstoetter, Barbara Nell, Klara Klein, Georg Mlynek, Lukas Wimmer, Lisa Scheiblecker, Alexander Tichy, Andrea Hoelbl-Kovacic |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Veterinary Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12917-025-04592-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
by: Valory Anne S. Vailoces, et al.
Published: (2025-04-01) -
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
by: Yuankai Shi, et al.
Published: (2025-07-01) -
Role and Mechanisms of Angiogenesis in Tumours
by: Aleksandra Sobczyńska-Rak, et al.
Published: (2025-06-01) -
Angiogenesis Induced by HIF1α and VEGF as Pathophysiological Cause of Glaucoma
by: Burim Neziri, et al.
Published: (2025-06-01) -
Serum vascular endothelial growth factor levels in bitches with canine transmissible venereal tumors treated with vincristine sulphate
by: Esra Kocabaş, et al.
Published: (2021-06-01)